-
-
Call more information
660-596-2224 -
For far too many years, pain researchers and clinicians have relied on the concept of the morphine equivalent daily dosage (MEDD), or some variant of it, as a means of comparing the “relative corresponding quantity” of the numerous opioid molecules that are important tools in the treatment of chronic pain. This concept dates back to […]
Read MoreVirtual reality (VR), already shown to have important benefits in the treatment of acute and procedural pain, shows preliminary evidence of also reducing symptoms in chronic pain, according to new research. “Our pain providers desperately need effective nonopioid treatments for chronic pain, ones that patients will adopt and use,” Ted Jones, PhD, from the Behavioral […]
Read MoreA mathematical model developed by researchers at Loyola University in Chicago can predict the length of time patients with hepatitis C virus (HCV) must remain on direct-acting antiviral (DAA) drugs to achieve sustained virologic response, according to a new study. The investigators used early viral kinetic analysis to test study participants—58 people with HCV being […]
Read MoreCollegium announced that the FDA has approved oxycodone (Xtampza ER) extended-release capsules, a twice-daily medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The drug uses Collegium’s proprietary DETERx abuse-deterrent technology platform, and is designed to provide adequate pain control while […]
Read MoreThe routine use of apneic oxygenation during endotracheal intubation of critically ill adults does not necessarily increase oxygen saturation compared with usual care, a recent study has concluded. “Interventions that appear effective in the highly controlled environment of the operating room [OR] frequently fail to translate to critically ill patients in the ICU,” said Matthew […]
Read More